Clinical trials: Stage II Skin Cancer
TNBC, Triple Negative Breast Cancer
QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer
This study is a single-arm, multicenter, prospective phase II clinical trial designed to evaluate the efficacy and safety of QL1706 in combination with anlotinib hydrochloride and nab-paclitaxel as first-line treatment for…
- Trial name
- NCT07601178
- Testing
- TREATMENT GROUP（QL1706 + anlotinib+ nab-paclitaxel ）
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Breast Cancer, Breast Cancer Female
Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer
The standard treatment for breast cancer when cancer cells were found near or within the margins of the tissue that is removed during breast surgery, is radiation of the entire chest wall.
- Conditions
- Breast Cancer, Breast Cancer Female, DCIS, Stage II Breast Cancer
- Trial name
- NCT05436808
- Testing
- Partial Chest Wall Radiation Therapy
- Where
- United States
- Sponsor
- Stony Brook University
HER2-positive Breast Cancer
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
The purpose of the study is to find out if an investigational drug called Dendritic Cell (DC1) vaccine added to standard neoadjuvant (given before main treatment) therapy can help people with HER2 (human epidermal growth factor…
- Trial name
- NCT05325632
- Testing
- HER-2 pulsed DC1, Trastuzumab, Pertuzumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Condylomata Acuminata, Papillomavirus Infections
Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)
Ranpirnase in topical formulation is an antiviral drug being evaluated for the topical treatment of anogenital warts. The aims of this study is to evaluate the efficacy and safety of a topical formulation of ranpirnase in…
- Conditions
- Condylomata Acuminata, Papillomavirus Infections, Sexually Transmitted Diseases
- Trial name
- NCT02535104
- Testing
- Ranpirnase, Vehicle
- Where
- Bolivia
- Volunteers
- 70 people
- Sponsor
- Tamir Biotechnology, Inc.
Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer
MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
The purpose of this study is to test whether patients undergoing a breast MRI (magnetic resonance imaging) before breast surgery will have better results after the surgery.
- Conditions
- Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer
- Trial name
- NCT01805076
- Testing
- Breast surgery, Magnetic resonance imaging, Mammography
- Where
- 179 sites in United States
- Volunteers
- 319 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Osteoporosis
Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer
RATIONALE: It is not yet known whether zoledronate is effective in preventing bone loss in premenopausal women who are receiving adjuvant chemotherapy after undergoing surgery for early stage breast cancer.
- Trial name
- NCT00049452
- Testing
- zoledronic acid
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Breast Cancer
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer
The purpose of this study is to evaluate the safety and time to progression of HLA-A*0201 restricted epitope peptides VEGFR1 and VEGFR2 emulsified with Montanide ISA 51 in advanced breast cancer patients.
- Trial name
- NCT00677326
- Testing
- VEGFR1 and VEGFR2
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- Tokyo University
Breast Cancer
Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and genistein, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00244933
- Testing
- genistein, gemcitabine, Tumor biopsy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
HER 2 Positive Advanced Breast Cancer, Breast Cancer
Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer
The JAZMINE study is a multicenter, open-label, non-comparative, phase Ib/II clinical trial to evaluate safety and preliminary efficacy of zanidatamab in combination with tucatinib and chemotherapy (capecitabine or eribulin…
- Trial name
- JAZMINE (NCT07494448)
- Testing
- Zanidatamab, Tucatinib, Capecitabine
- Volunteers
- 24 people
- Sponsor
- MedSIR
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain
Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases
This phase II trial studies how well stereotactic radiosurgery works in treating patients with melanoma that has spread to more than 3 places in the brain.
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT01644591
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma
This will be a phase II trial of the combination of sunitinib and nivolumab in patients with advanced, measurable, metastatic melanoma who harbor mutations in the KIT gene in their tumors.
- Trial name
- NCT02400385
- Testing
- sunitinib, nivolumab
- Where
- United States
- Sponsor
- California Pacific Medical Center Research Institute
Kidney Cancer, Melanoma (Skin)
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy in treating patients with newly diagnosed brain metastases from kidney cancer…
- Conditions
- Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer
- Trial name
- NCT00003308
- Testing
- stereotactic radiosurgery
- Where
- 14 sites in United States, Australia and 2 more
- Sponsor
- Eastern Cooperative Oncology Group
Breast Cancer
Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as docetaxel, epirubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00398489
- Testing
- trastuzumab, anastrozole, cyclophosphamide
- Where
- 5 sites in Germany
- Volunteers
- 94 people
- Sponsor
- Technical University of Munich
Metastatic Breast Cancer
Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer
Metastatic breast cancer (MBC) is an incurable disease and is needed to improve effective chemotherapy. Paclitaxel plus Gemcitabine (PG) combination chemotherapy is one of the preferred chemotherapeutic regimens for patients with…
- Trial name
- EG_PG (NCT02263495)
- Testing
- Paclitaxel, Eribulin, Gemcitabine
- Where
- 2 sites in South Korea
- Volunteers
- 118 people
- Sponsor
- Asan Medical Center
Breast Cancer, Metastatic Breast Cancer
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
This is a phase 2, open-label, singled-arm clinical trial determining efficacy of combination therapy with anastrozole, fulvestrant and abemaciclib in subjects with breast cancer.
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
- Trial name
- NCT05524584
- Testing
- Fulvestrant, Anastrozole, Abemaciclib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Irvine
Breast Cancer
Herbal Therapy in Treating Women With Metastatic Breast Cancer
RATIONALE: The Chinese herb Scutellaria barbata contains ingredients that may slow the growth of cancer cells and may be an effective treatment for metastatic breast cancer.
- Trial name
- NCT00028977
- Testing
- herba scutellaria barbata, herba scutellaria Barbatae (HSB)
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Francisco
Melanoma (Skin)
Boron Neutron Capture Therapy in Treating Patients With Melanoma
RATIONALE: Boron neutron capture therapy may selectively kill tumor cells without harming normal tissue. PURPOSE: Phase II trial to study the effectiveness of boron neutron capture therapy in treating patients who have melanoma.
- Trial name
- NCT00059800
- Testing
- boron neutron capture therapy
- Where
- 2 sites in United States
- Sponsor
- Beth Israel Deaconess Medical Center
Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer
Fulvestrant + Neratinib In Breast Cancer
This is a Phase 2 open label, multi-center non-randomized interventional study designed to evaluate the safety and efficacy of combining Neratinib plus Fulvestrant in previously treated metastatic HR-positive, HER2-negative…
- Conditions
- Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
- Trial name
- HER2-Signal (NCT04901299)
- Testing
- NERATINIB, FULVESTRANT
- Where
- 2 sites in United States
- Sponsor
- Massachusetts General Hospital
Breast Cancer, Breast Cancer Stage II-III
Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer
Neoadjuvant (preoperative) chemotherapy is an interesting research tool which allows investigators to test new drugs and/or new schedules with a validated surrogate endpoint, pCR.
- Trial name
- NCT01560663
- Testing
- Docetaxel- Carboplatin
- Where
- Spain
- Volunteers
- 415 people
- Sponsor
- Miguel Martín Jiménez
Adenoid Cystic Carcinoma, Squamous Cell Carcinoma
Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy
The purpose of this study is to test the hypothesis that 1)intensity-modulated radiotherapy (IMRT) or proton radiation therapy would result in improved local control rate and lowered toxicity compared to conventional…
- Conditions
- Adenoid Cystic Carcinoma, Squamous Cell Carcinoma, Sinonasal Carcinoma, Sinonasal Undifferentiated Carcinoma
- Trial name
- NCT01586767
- Testing
- Proton radiation therapy, Intensity-modulated radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Massachusetts General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.